title: The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
abstract: BACKGROUND
  Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a coregulator of the estrogen receptors (ERs) alpha and beta, is a potential proto-oncogene in hormone dependent gynecological malignancies. To better understand the role of PELP1 in epithelial ovarian cancer (EOC), the protein expression and prognostic significance of PELP1 was evaluated together with ERalpha and ERbeta in EOC tissues.
  
  
  METHODS
  The expression of PELP1, ERalpha, and ERbeta was characterized in tumor tissues of 63 EOC patients. The prognostic value was calculated performing log-rank tests and multivariate Cox-Regression analysis. In a second step, validation analysis in an independent set of 86 serous EOC patients was performed.
  
  
  RESULTS
  Nuclear PELP1 expression was present in 76.2% of the samples. Prevalence of PELP1 expression in mucinous tumors was significantly lower (37.5%) compared to serous (85.7%) and endometrioid tumors (86.7%). A significant association between PELP1 expression and nuclear ERbeta staining was found (p=0.01). Positive PELP1 expression was associated with better disease-free survival (DFS) (p=0.004) and overall survival (OS) (p=0.04). The combined expression of ERbeta+/PELP1+ revealed an independent association with better DFS (HR 0.3 [0.1-0.7], p=0.004) and OS (HR 0.3 [0.1-0.7], p=0.005). In the validation set, the combined expression of ERbeta+/PELP1+ was not associated with DFS (HR 0.7 [0.4-1.3], p=0.3) and OS (HR 0.7 [0.3-1.4], p=0.3).
  
  
  CONCLUSIONS
  Positive immunohistochemical staining for the ER coregulator PELP1, alone and in combination with ERbeta, might be of prognostic relevance in EOC.
authors.affiliation: Department of Gynaecology and Gynaecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Aust
authors.forename: Peter
authors.initials: P
authors.lastname: Horak
authors.forename: Dietmar
authors.initials: D
authors.lastname: Pils
authors.forename: Sophie
authors.initials: S
authors.lastname: Pils
authors.forename: Christoph
authors.initials: C
authors.lastname: Grimm
authors.forename: Reinhard
authors.initials: R
authors.lastname: Horvat
authors.forename: Dan
authors.initials: D
authors.lastname: Tong
authors.forename: Bernd
authors.initials: B
authors.lastname: Schmid
authors.forename: Paul
authors.initials: P
authors.lastname: Speiser
authors.forename: Alexander
authors.initials: A
authors.lastname: Reinthaller
authors.forename: Stephan
authors.initials: S
authors.lastname: Polterauer
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism*; D056970:Co-Repressor Proteins / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D046228:Microarray Analysis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism*; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D012044:Regression Analysis; D016019:Survival Analysis; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D056970:Co-Repressor Proteins; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; C000715470:MAS1 protein, human; C438485:PELP1 protein, human; D000090063:Proto-Oncogene Mas; D014157:Transcription Factors